845
845
788
788
756
756
708
708
775
775
737
737
860
860
858
858
988
988
1627
1627
2019
2010
University (24.4K)Research Institution (1K)Company (986)Hospital (614)Foundation (260)Investor (58)Other (19)
1 - 10 of 24,411
Sort by
Clinical Trial
Clinical Trial IDNCT04001114Start Date2020-02-01Completion Date2021-11-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population. Dependent tobacco smoking is controlled by how different aspects of cigarette smoking are perceived. There is evidence suggesting that people with schizophrenia differ in how they perceive cigarette smoking, which, if confirmed, would have implications for tailoring treatment interventions for smoking cessation …
Clinical Trial
Clinical Trial IDNCT04181684Start Date2020-02-01Completion Date2023-02-01PhaseN/AStudy TypeInterventionalStatusNot yet recruiting
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.
Clinical Trial
Clinical Trial IDNCT04140526Start Date2020-02-01Completion Date2023-02-01PhasePhase 1/Phase 2Study TypeInterventionalStatusNot yet recruiting
This is a First-in-Human Phase I/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
Clinical Trial
Clinical Trial IDNCT04169360Start Date2020-01-01Completion Date2021-05-01PhasePhase 2Study TypeInterventionalStatusNot yet recruiting
This is a double blind, placebo controlled, randomized trial to evaluate the safety and preliminary efficacy of ANS-6637 in adults with opioid use disorder with and without opioid agonist therapy. Patients will be randomized to two arms: (1) ANS-6637 for three months vs (2) Placebo for three months. Subjects will subsequently be followed for an additional one month post treatment.
Research Grant
Award Number1941355Funding AgencyNational Science FoundationEffective Date2020-01-01Expiration Date2020-12-31Funding Amount$129,300
Pain is a distressing feeling often caused by intense or damaging stimuli and commonly defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. In clinical medicine, pain is often regarded as a symptom of an underlying condition. Since pain is a complex and subjective phenomenon, objectively defining pain has been difficult. This project is designed to develop machine learning and computer algorithms for enhanced and objective pain recogniti…
Clinical Trial
Clinical Trial IDNCT04050280Start Date2020-01-01Completion Date2023-02-01PhasePhase 2Study TypeInterventionalStatusNot yet recruiting
This study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" [cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)] in the treatment of acute myeloid leukemia (AML) that has not responded well to standard therapy or has returned after an initial remission (relapsed). The trial will be conducted at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC). Potential participants will go through a screenin…
Publication
ID31579936Published Date2020-01-01JournalThe Journal of pathology, 2020-01-01, Volume 250
Molecular chaperones, many of which are heat shock proteins (Hsps), are components of the chaperoning system and when defective can cause disease, the chaperonopathies. Chaperone-gene variants cause genetic chaperonopathies, whereas in the acquired chaperonopathies the genes are normal, but their protein products are not, due to aberrant post-transcriptional mechanisms, e.g. post-translational modifications (PTMs). Since the chaperoning system is widespread in the body, chaperonopathies affec…
Publication
ID31698012Published Date2020-01-01JournalBrain, behavior, and immunity, 2020-01-01, Volume 83
Depression during pregnancy and the post-partum is common, with severe cases resulting in suicidal behavior. Despite the urgent and unmet medical need, the biological underpinnings of peri-partum depression remain unclear. It has been suggested that it is triggered by dynamic changes of the immune system during pregnancy and at delivery. Therefore, we investigated whether a pro-inflammatory status in plasma, together with changes in the kynurenine pathway activity, is associated with the deve…
Clinical Trial
Clinical Trial IDNCT04201600Start Date2020-01-01Completion Date2021-12-01Study TypeObservationalStatusNot yet recruiting
This study examines the association of variability in glucose values over a 10-day period with cognitive function and functional status among individuals with prediabetes, aged 50 or older.
Publication
ID31855464Published Date2019-12-19JournalBreastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 2019-12-19
Although reverse causation is well known in the breastfeeding-allergy arena, only a few studies have used a valid statistical method to test its occurrence. This study aimed to illustrate reverse causation between eczema and breastfeeding and to examine their effect estimate under this occurrence. Time-to-event data from the Infant Feeding Practices Study II were used. Model 1: early signs of eczema were modeled as a time-varying covariate to assess reverse causation using survival analysis a…
We found 24,411 documents that match your Search
Research Grants: 16,542
Publications: 2,746
Patents: 3,532
Clinical Trials: 856
Web Documents: 735

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in